Synapse - Pamela R Drullinsky

Pamela R Drullinsky

Drullinsky pamela

Groups

Hematologic Malignancies, Division of
Solid Tumor Oncology Division
- Breast Medicine Service

Research Focus

Medicine; Attending

1814

Recent additions – View all

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): One cohort of a phase 2, multicentre, open-label, non-comparative study
Journal Article

Rugo, H. S.; Lerebours, F.; Ciruelos, E.; Drullinsky, P.; Ruiz-Borrego, M.; Neven, P.; Park, Y. H.; Prat, A.; Bachelot, T.; Juric, D.; more...
Lancet Oncology (2021)

Fulltext@MSK | Save
Alpelisib + letrozole in patients with PIK3CA-mutated, hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) previously treated with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + fulvestrant: BYLieve study results
Meeting Abstract

Rugo, H. S.; Lerebours, F.; Juric, D.; Turner, N.; Chia, S.; Drullinsky, P.; Prat, A.; Vázquez, R. V.; Akdere, M.; Arce, C.; more...
Cancer Research (2021)

Fulltext@MSK | Save
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: The SANDPIPER trial
Journal Article

Dent, S.; Cortés, J.; Im, Y. H.; Diéras, V.; Harbeck, N.; Krop, I. E.; Wilson, T. R.; Cui, N.; Schimmoller, F.; Hsu, J. Y.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

Co-authors at MSK

Types of Work

Publications

Journal of Clinical Oncology (15)
Blood (14)
Breast Cancer Research and Treatment (9)
Cancer Research (8)
Hematological Oncology (5)
Clinical Breast Cancer (3)
Annals of Oncology (2)
Clinical Cancer Research (2)
Clinical Lymphoma, Myeloma and Leukemia (2)
Leukemia (2)